SCHEMBL15922502

SCHEMBL15922502

CCCC(N)(CCC)C12CC3CC(CC(C3)C1)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
MAPT P10636 2/20 0.35
GRIN2D O15399 4/20 0.34
GRIN3B O60391 4/20 0.34
GRIN1 Q05586 4/20 0.34
GRIN2A Q12879 4/20 0.34
GRIN2B Q13224 4/20 0.34
GRIN2C Q14957 4/20 0.34
GRIN3A Q8TCU5 4/20 0.34
SLC22A2 O15244 2/20 0.33
SLC47A1 Q96FL8 2/20 0.33
SLC22A1 O15245 1/20 0.33
TSHR P16473 1/20 0.33
NFKB1 P19838 1/20 0.33
STAT6 P42226 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15922449 0.82 GRIN2D (0.37) LMNASMN1; SMN2POLBTHRBBLM
SCHEMBL11676267 0.76 GRIN2D (0.36) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7462026 0.74 KMT2A (0.33) SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL931359 0.74 GRIN2D (0.30) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Ammonia Solution, Strong SCHEMBL28147128 0.74 GRIN2D (0.34) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Phosphine SCHEMBL4096380 0.72 EPHX2 (0.30)
Iodide SCHEMBL4096385 0.72
SCHEMBL7452744 0.72 KMT2A (0.33) SMN1; SMN2MEN1KMT2AHSD11B1
Hydrochloric Acid SCHEMBL9759546 0.72 LMNA (0.43) LMNASMN1; SMN2POLBTHRBBLM
SCHEMBL299469 0.69 GRIN2D (0.41) LMNASMN1; SMN2POLBTHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9840465-B2 Antiviral compounds UNIV BRIGHAM YOUNG (US) 2017-12-12 US disclosed
US-9840465-B2 Antiviral compounds UNIV BRIGHAM YOUNG (US) 2017-12-12 US disclosed
US-9840465-B2 Antiviral compounds UNIV BRIGHAM YOUNG (US) 2017-12-12 US disclosed
US-20150368196-A1 ANTIVIRAL COMPOUNDS UNIV BRIGHAM YOUNG (US) 2015-12-24 US disclosed
US-20150368196-A1 ANTIVIRAL COMPOUNDS UNIV BRIGHAM YOUNG (US) 2015-12-24 US disclosed
EP-2950789-A2 ANTIVIRAL COMPOUNDS Brigham Young University (US) 2015-12-09 EP disclosed
WO-2014121170-A2 ANTIVIRAL COMPOUNDS BRIGHAM YOUNG UNIVERSITY (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368196-A1 ANTIVIRAL COMPOUNDS ACE, ADA, MAVS LMNA 2844/4885SMN1; SMN2 4527/4885POLB 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.